{
  "id": 10630807,
  "title": "Astrazeneca invests $2bn in cancer drug tie-up",
  "url": "https://urgent.news/2026/09/29/astrazeneca-invests-2bn-in-cancer-drug-tie-up",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-29T06:36:50.000Z",
  "source": {
    "name": "City AM",
    "slug": "city-am",
    "url": "https://www.cityam.com/astrazeneca-invests-2bn-in-cancer-drug-tie-up/"
  },
  "original_language": "en",
  "account": "Astrazeneca, a major UK-based pharmaceutical company, has announced a $2 billion investment in US-based Summit Therapeutics. The investment involves the purchase of 109,000 shares in Summit, trading at $18.36 per share, which is an 18.6 percent premium over Summit's closing price of $15.48. The partnership aims to collaborate on various cancer research studies, focusing on the development of ivonescimab, a new drug designed to combat cancer's evasion of the immune system and growth of blood vessels. This deal is expected to culminate at the end of the week, giving Astrazeneca a 12 percent shareholding in Summit's outstanding stock. Susan Galbraith, Astrazeneca's executive vice president of oncology, believes the collaboration could lead to innovative treatments, potentially raising the standard for cancer care. Astrazeneca's CEO, Maky Zanganeh, described the partnership as the beginning of \"an exciting new chapter\" in the advancement of cancer treatments. The move comes after AstraZeneca saw a six percent drop in share value following rumors of a potential $400 billion merger with Bristol Meyers Squibb, a deal that caused concerns over its financial and structural implications.",
  "summary": "Astrazeneca has invested $2bn in US pharmaceutical firm Summit Therapeutics as part of a blockbuster cancer research tie-up. The FTSE 100 drugs giant has agreed to buy 109,000 shares in Nasdaq-listed Summit for $18.36 per share as part of the deal. The tie-up will see the two pharma giants collaborate on a series of studies [...]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}